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Abstract 
The role of oxidation in the development of age-related eye disease has prompted interest in 
the use of nutritional supplementation for prevention of onset and progression. Our aim is to 
highlight possible contraindications and adverse reactions of isolated or high dose ocular 
nutritional supplements. Web of Science and PubMed database searches were carried out, 
followed by a manual search of the bibliographies of retrieved articles. Vitamin A should be 
avoided in women who may become pregnant, in those with liver disease, and in people who 
drink heavily. Relationships have been found between vitamin A and reduced bone mineral 
density, and beta-carotene and increased risk of lung cancer in smoking males. Vitamin E and 
Ginkgo biloba have anticoagulant and anti-platelet effects respectively, and high doses are 
contraindicated in those being treated for vascular disorders. Those patients with 
contraindications or who are considered at risk of adverse reactions should be advised to seek 
specialist dietary advice via their medical practitioner. 
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Introduction 
People are increasingly taking an active interest in their well-being, and seeking alternative 
medical therapies (Eisenberg et al., 1998; Gilbert, 1999). Traditional health-care providers have 
been perceived to have a negative attitude towards these therapies (Goodwin and Tangum, 
1998). This may explain why many people do not consider their medical practitioner a major 
source of nutritional information (Schutz et al., 1982; Barr, 1986; Levy and Schucker, 1987) and 
do not always report unconventional therapy use to their physicians (Eisenberg et al., 1993).  
 
Use of ocular nutritional supplementation has been investigated with regard to prevention of 
onset or progression of glaucoma, cataract, and age-related macular disease. There is 
particular interest in the use of nutrition as a prevention and treatment strategy for age-related 
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macular degeneration (AMD) as it is the leading cause of visual disability in the developed 
World (Klein et al., 1997), and because treatment options are currently lacking (Zarbin, 2004).  
 
Eye-care practitioners require information about the benefits, and potential hazards, of ocular 
nutritional supplements in order to be able to discuss their use with patients. It should be 
emphasised that the risk of side effects from nutrients is much lower than from over the counter 
or prescription drugs. As an example, the National Health and Nutrition Examination Survey II 
estimated that 35 % of the US population use vitamin A supplements (Koplan et al., 1986), and 
the rate of toxic reactions has been reported as 1 case per 1.1 million per year exposed. 
 
The aim of this review is to highlight possible contraindications and the potential for adverse 
reactions for those nutrients reported to be beneficial to ocular health. 
 
Methods 
We identified pertinent articles on nutrition, nutritional toxicity, and ocular disease published in 
peer-reviewed journals, through a multi-staged, systematic approach. In the first stage, a 
computerized search of the PubMed database (National Library of Medicine) and the Web of 
Science database was performed to identify all articles about nutrition and ocular disease 
published between 1980 and July 2004. The terms ‘ocular disease AND nutrition’, ‘nutritional 
supplement AND adverse reactions’, and ‘nutritional supplement AND contraindications’ were 
used for a broad search. In the second stage all abstracts were examined to identify articles that 
described the use of nutrients in ocular disease. Copies of the entire articles were obtained. 
Bibliographies of the retrieved articles were manually searched with use of the same search 
guidelines. In the third stage, articles were reviewed and information relating to the toxicity of 
those nutritional supplements reported to be beneficial for ocular health was incorporated in to 
the manuscript. 
 
Terminology 
In accordance with the International Classification and Grading System for Age-Related 
Maculopathy (ARM), and Age-Related Macular Degeneration (AMD) (Bird et al., 1995), these 
abbreviations will be used throughout. The term age-related macular disease will be used to 
encompass ARM and AMD.  Dietary Reference Values (DRV) were established in 1991 to 
replace Recommended Daily Allowances (RDA).  The term DRV is used to cover Lower 
Reference Nutrient Intake (LNRI), Estimated Average Requirement (EAR), Reference Nutrient 
Intake (RNI), and safe intake (Mason, 2001). RNI refers to the amount of protein, vitamin or 
mineral that is sufficient for almost every individual to maintain good health. 
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Nutrition in prevention of disease 
The human body has complex defence systems to combat the damage caused by activated 
oxygen. Nutrients involved in this defence process include the minerals selenium, copper, 
magnesium, and zinc, the vitamins E, C and A, and the carotenoids.  
 
Damaging forms of oxygen can be referred to as reactive oxygen species (ROS). ROS is an 
umbrella term used to describe free radicals, singlet oxygen, and hydrogen peroxide. Free 
radicals have an unpaired electron in their outer orbits, which makes them damaging to the 
body. In order to achieve stability they pluck electrons from other molecules, producing further 
ROS and fuelling a disease-generating cytotoxic chain reaction. Examples of free radicals 
include the superoxide anion radical, formed from the reduction of molecular oxygen to water, 
and the hydroxyl radical. The hydroxyl radical is particularly damaging as it can take electrons 
from almost any organic molecule.  
 
The reduction of oxygen to water also produces hydrogen peroxide, which interacts with the 
superoxide anion radical to form the hydroxyl radical. Although singlet oxygen does not have an 
unpaired electron in its outer orbit, it does have a peripheral electron that is excited to an orbital 
above that which it normally occupies, making it highly reactive (Diplock, 1991).  
 
The hydroxyl radical is the biggest potential threat to living systems because of its high 
reactivity, which does however, suggest that it is likely to have a short in vivo half-life (Diplock, 
1991). Singlet oxygen is scavenged by vitamin A and other retinoids, as well as beta-carotene 
(Levin et al., 1997) and other carotenoids (Di Mascio et al., 1989). The superoxide anion radical 
is efficiently removed by the enzyme superoxide dismutase (SOD), which in the mitochondria 
contains manganese, and in the cytosolic compartment contains copper and zinc. Hydrogen 
peroxide is metabolised by the selenium-containing enzyme, glutathione peroxidase. 
 
Polyunsaturated fatty acids are particularly vulnerable to attack by the hydroxyl radical resulting 
in production of lipid peroxyl radicals and lipid hydroperoxide. The formation of lipid 
hydroperoxides is dependant on the availability of hydrogen, which can be obtained from 
vitamin E or from other polyunsaturated fatty acid molecules. The use of vitamin E as the donor 
is preferable, as it prevents the production of more free radicals and the initiation of chain 
reactions. The resultant vitamin E radical is though to be reformed to vitamin E via a system 
involving vitamin C and glutathione (Tappel, 1962). 
 
Ocular tissues are particularly susceptible to oxidative damage. The transparency of the cornea, 
aqueous humor, lens and retina allow continuous exposure to light, which along with aging, 
inflammation, air pollutants, and cigarette smoke, has been shown to increase production of 
ROS (Borish et al., 1987; Machlin and Bendich, 1987). The role of oxygen in cataract formation 
Page 4 of 30 
has been demonstrated (Schocket et al., 1972) and the retina is particularly vulnerable because 
of its abundance of polyunsaturated fatty acids, the occurrence of phagocytosis within the RPE, 
and the fact that it has much higher blood flow than other tissues. Phagocytosis results in the 
production of ROS and high blood flow increases the availability of oxygen. 
 
The antioxidant network 
A system of antioxidant nutrients exists to neutralize ROS. Vitamin C reacts with superoxide in 
the aqueous phase, and vitamin E reacts with peroxy radicals in the lipophilic phase. In the 
process, vitamins C and E themselves become free radicals. However, they have aromatic ring 
structures, which delocalize the unpaired electron and are therefore less reactive. They also 
form part of the ‘antioxidant network’, in which vitamin C is able to regenerate vitamin E from the 
vitamin E radicals (Packer, 2001a).  
 
Alpha lipoic acid is a vitamin-like antioxidant that is soluble in both fat and water (Kagan et al., 
1990). It is manufactured within the body and is also found in food such as liver and yeast. 
Dihydrolipoic acid (DHLA), a powerful metabolic antioxidant, is formed when alpha lipoic acid is 
reduced by enzymes. DHLA has an important role in antioxidant defence through maintenance 
of high levels of the reduced (potent) forms of vitamins C and E. Alpha-lipoic acid also boosts 
cellular levels of glutathione, a major cellular antioxidant. Levels of glutathione decline with age, 
and low levels are associated with higher incidence of disease in the older people. Glutathione 
concentrations are recognised as a predictor of the susceptibility to disease as well as a marker 
of biological age (Packer, 2001b). 
 
Review of nutrients 
Nutrients that are considered to be beneficial for ocular health have already been reviewed 
(Bartlett and Eperjesi, 2004) and include vitamins A, B, C and E, beta-carotene, 
lutein/zeaxanthin, magnesium, selenium, zinc, essential fatty acids, and Ginkgo biloba (see 
table 1). Drug interactions of these nutrients are shown in table 2. 
 
Insert tables 1 and 2 about here. 
 
Vitamin A 
Humans obtain vitamin A in two forms; provitamin A (carotenoids), found mainly in foods of 
plant origin such as green leafy vegetables or yellow fruit, and preformed vitamin A from animal 
products such as milk, meat, and liver (Combs, 1998). Provitamin  A compounds can be split 
oxidatively into forms of vitamin A. Vitamin A is essential for maintaining the integrity of epithelial 
tissues, and normal growth and differentiation of epithelial cells.  It is also involved with 
reproduction, and the growth of developing bony structures (Burton and Foster, 1988). Pro-
vitamin A in the form of beta-carotene was used in combination with other nutrients for the Age-
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Related Eye Disease Study (AREDS) (The AREDS Research Group, 2001b) and the Roche 
European American Cataract Trial (REACT) (The REACT Group, 2001). These randomised 
controlled trials (RCTs) found positive effects of intervention for age-related macular disease 
and cataract respectively. 
 
Provitamin A is not considered to be potentially toxic as the efficiency of absorption falls with 
increased dietary intake (Brubacher and Weiser, 1985). Absorption of preformed vitamin A, 
however, remains efficient (approximately 90%) even when dietary intake is high; absorption of 
high dose supplements is closer to 50%.  When high doses of preformed vitamin A are 
consumed, oxidation produces retinoic acid, which has a potent effect on differentiation and 
gene expression (Allen and Haskell, 2002). Vitamin A capsules are available without 
prescription in concentrations of 25 000 IU. The estimated daily biological requirement for 
vitamin A is 2667 IU retinol for women and 3300 IU retinol for men (National Research Council, 
1989). Marketing of vitamin A for treatment of acne and certain cancers may result in high dose 
supplementation and increase the risk of toxicity. 
 
Lutein/zeaxanthin 
Lutein, and its stereo-isomer, zeaxanthin, are xanthophylls, and are the only carotenoids found 
in human serum that are also found in the retina and macula (Bone et al., 1985; Handelman et 
al., 1988; Handeman et al., 1992) and the crystalline lens (Yeum et al., 1995).  It has been 
suggested that they play a similar role in humans as in plants, as antioxidants and screeners of 
high-energy blue light (Krinsky, 2002). 
 
In the retina they are termed the macular pigment (MP). Zeaxanthin dominates in the macula 
centre, whereas, lutein is more abundant in the medial and peripheral macula (Bone et al., 
1997). This suggests a possible protective role of lutein for rod photoreceptors (Sommerburg et 
al., 1999) and of zeaxanthin for the central cone photoreceptors (Bone et al., 1988).  
 
The MP may prevent light-initiated oxidative damage to the retina and therefore protect against 
subsequent age-related deterioration (Hammond et al., 1998). The absorbance spectrum of MP 
peaks at 460 nm. It is purported to act as a broadband filter, reducing the sensitivity of the 
macular region to short wavelength light that is most damaging in the 440 to 460 nm range 
(Reading and Weale, 1974; Pease et al., 1987). Zeaxanthin is reported to be a superior photo-
protector during prolonged UV exposure; the shorter time-scale of protective efficacy of lutein 
has been attributed to oxidative damage of the carotenoid itself (Sujak et al., 1999).  
 
The MP also acts as a scavenger of ROS. The relatively high concentration of MP in the inner 
retinal layers (Snodderly et al., 1984) is very likely to indicate a photoprotective role, while the 
presence of MP in the rod outer segments (Sommerburg et al., 1999), is suggestive of a ROS-
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quenching function. Lutein and zeaxanthin have been found in higher concentration in the rod 
outer segments of the perifoveal retina than the peripheral retina, again lending support to their 
proposed protective role in age-related macular disease (Rapp et al., 2000). 
 
The carotenoid lutein has been investigated with regard to preventing onset and progression of 
age-related macular disease and has been shown to improve measures of visual function in 
AMD patients (Richer et al., 2004). In a South Pacific population, daily intake of an average of 
26 mg/day of lutein yielded no apparent side-effects (Le Marchand et al., 1995). 
 
B vitamins: B2, B6, and B12  
The B vitamins are water soluble. Vitamin B2 (riboflavin) acts as an antioxidant, has a role in 
synthesis of steroids and red blood cells, and in maintaining the integrity of mucous membranes 
(Expert Group on Vitamins and Minerals, 2003). Vitamin B6 (pyroxidine) refers to a group of 
nitrogen-containing compounds with three primary forms: pyridoxine, pyridoxal, and 
pyridoxamine. B6 participates in over 100 enzymatic reactions and  has a reported role in 
gluconeogenesis (Leklem, 1988), lipid metabolism (Birch, 1938), erythrocyte metabolism 
(Bottomley, 1983), and immune function (Robson and Schwarz, 1975; Talbott et al., 1987; 
Meydani et al., 1991; Rall and Meydani, 1993). Cobalamin (B12) is an essential cofactor for two 
enzymes: methylmalonyl-CoA mutase  is needed for fatty acid metabolism, and methionine 
synthase (Stubbe, 1994), which controls nucleic acid synthesis and methylation reactions within 
the body.  Deficiency leads to megaloblastic anaemia via reduced production of red blood cells 
and cobalamin-associated neuropathy.  
 
Vitamins B6 and B12 and folate (folic acid) regulate homocysteine concentrations in the blood - 
a risk factor for cardiovascular disease. There is a reported increased risk of coronary heart 
disease (CHD) or ischaemic stroke associated with low folate intake or low blood folate levels 
(Eikelboom et al., 1999). In meta-analysis (Homocysteine Lowering Trialists' Collaboration, 
1998), folate lowered plasma homocysteine levels by 25 %, and addition of B12 lowered levels 
by a further 7 %. 
 
 Vitamins B2 (Leske et al., 1991; Kuzniarz et al., 2001) and B12 (Kuzniarz et al., 2001) have 
been linked with a reduced risk of cataract.  
 
Vitamin C 
Almost 35 % of the US population use vitamin C (ascorbic acid) supplements. Side effects are 
rare and there appear to be no contraindications for doses of up to 2 mg/day (Bloch, 2000). It is 
water soluble, reduces platelet aggregation (Wilkinson et al., 1999), and may be important in 
lowering blood pressure (Taddei et al., 1998). RCTs investigating the effect of vitamin C in 
combination with other nutrients found a positive effect for progression of AMD (The AREDS 
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Research Group, 2001b) and a small positive effect for cataract (The REACT Group, 2001), 
although no effect against cataract has also been reported (The AREDS Research Group, 
2001a). 
 
Vitamin E 
Alpha-tocopherol is the most effective antioxidant of the vitamin E group, and protects against 
lipid peroxidation (Machlin, 1980). RCTs investigating the effect of vitamin E supplementation 
on incidence or progression of age-related macular disease have found no positive effect 
(Teikari et al., 1998; Taylor et al., 2002), although positive effects of vitamin E supplementation 
in combination with other nutrients have been reported for progression of AMD (The AREDS 
Research Group, 2001b) and cataract (The REACT Group, 2001). Several studies have found 
no adverse reactions with vitamin E supplementation in normals (Tsai et al., 1978; Stampfer et 
al., 1983; Kitigawa and Mino, 1989) cardiac patients (Inagaki et al., 1978), angina pectoris 
patients (Anderson and Reid, 1974; Gillian et al., 1977), and diabetic patients (Steinberg, 1993). 
 
Zinc 
Zinc is an essential component of over 200 enzymes, including antioxidant enzymes such as 
superoxide dismutases (Machlin and Bendich, 1987). Evidence for (Newsome et al., 1988) and 
against (Stur et al., 1996) a role of zinc supplementation in prevention of progression or 
development of AMD is presented by RCTs, although the positive result may be treated with 
caution (Bartlett and Eperjesi, 2003). Zinc acts as a cofactor for the antioxidant enzymes retinal 
dehydrogenase and catalase (Sigel, 1983) and is also involved in retinal metabolism.  
 
Selenium 
Selenium is a constituent of the enzyme glutathione peroxidase, which protects cell membranes 
from oxidative damage (Rotruck et al., 1973; Singh et al., 1984). Glutathione peroxidase 
metabolises hygrogen peroxide, thereby reducing the risk of free-radical mediated oxidative 
damage. The efficiency of gluthione peroxidase depends on the nutritional availability of 
selenium (Diplock, 1991). 
 
Animal studies have shown evidence for a protective role of selenium against development of 
cataract (Langle et al., 1997), and a marginal relationship between elevated selenium intake 
and reduced risk of cataract has been proposed (Valero et al., 2001).  
 
Magnesium 
Magnesium is related to the stability of cell walls and membranes, and many magnesium-
containing enzymes are involved in metabolic processes (Gibson and Reif, 1985; Pasquare and 
Giusto, 1993; Salvadore and Giusto, 1998). The retina contains many magnesium-containing 
enzymes that may be related to retinal physiological function (Gong et al., 2001). Magnesium 
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deficiency has been shown to induce multifocal necrosis in RPE cells of the rat (Gong et al., 
2001) and this trace element is essential for maintenance of the structure and function of the 
cornea (Gong et al., 2003). 
 
Ginkgo biloba 
Ginkgo biloba has the following functions; reduction of platelet aggregation and reduction of the 
development of free radicals (Chung et al., 1987; Braquet and Hosford, 1991), increasing 
vasodilation and reducing blood viscosity (Jung et al., 1990), quenching of free radicals (Robak 
and Gryglewski, 1988; Pincemail et al., 1989), and a role in neurotransmitter metabolism 
(Defeudis, 1991). Ginkgo biloba is marketed as a supplement to increase mental alertness and 
treat peripheral vascular disorders. One of its components is an inhibitor of the platelet 
aggregating factor (Rosenblatt and Mindel, 1997), and it has also been found to contain a 
natural nerve toxin (Arenz et al., 1996). 
 
One RCT found an improvement in visual acuity (VA) in AMD patients who supplemented with 
ginkgo biloba extract (GBE) (Lebuisson et al., 1986), although it has been suggested that these 
results should be treated with caution (Evans, 2000). GBE has also been reported to improve 
pre-existing visual field damage in normal tension glaucoma (Quaranta et al., 2003). 
 
Essential fatty acids 
Saturated fats consist of a chain of four to 22 carbon atoms. The carbon atoms within the chain 
are linked to two hydrogen atoms. At one end of the chain the carbon atom is linked to three 
hydrogen atoms, and at the other end of the chain the carbon atom is linked to an oxygen atom 
and an oxygen and a hydrogen atom. This is called the carboxyl end and forms the acid group 
of the molecule. Within the carboxyl group, the lone oxygen atom is linked to the final carbon 
atom with a double bond.  
 
Essential fatty acids (EFA) are polyunsaturated. This means that they contain double bonds 
within their carbon chains. Linoleic acid is an 18 carbon chain fatty acid with two double bonds 
in the middle of the chain. As a result, it is missing four hydrogen atoms, all on one side. The 
first double bond occurs at the sixth carbon atom. For this reason, linoleic acid is often referred 
to as omage-6 EFA. Because of its four missing hydrogen atoms, omega-6 EFA is fairly 
unstable, and reacts with light and oxygen. 
 
Alpha linoleic acid is an 18 carbon fatty acid with three double bonds. This means that it is 
missing six hydrogen atoms, all on one side. The first double bond occurs at the third carbon 
atom and so alpha linoleic acid is known as omega-3 EFA, and is sometimes referred to as a 
super unsaturated fatty acid (SUFA). This molecule is very unstable and readily reacts with light 
and oxygen. 
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Sources of omega-6 EFA include oils made from safflower, sunflower, corn, soya, evening 
primrose, pumpkin, and wheatgerm, as well as, dairy products, beef, poultry and eggs. Sources 
of omega-3 EFA include oils made from flaxseeds, mustard seeds, pumpkin seeds, soya bean, 
walnut oil, green leafy vegetables, and grains. Omega-3 and omega-6 EFA are converted within 
the body to other polyunsaturated fatty acids (PUFA) including EPA (eiocosapentaenoic acid), 
DHA (docosahexaenoic acid) and arachidonic acid. EPA and DHA are found in mackerel, 
salmon, sardines, sablefish, anchovies, and cod liver oil (Mann and Skeaff, 2002). Fish oil 
supplements usually contain 18 % EPA and 12 % DHA. 
 
Within the body, PUFAs are needed for maintaining cell membranes, and making 
prostaglandins, which regulate many body processes such as inflammation and blood clotting. 
Omega-3 EFA have been linked with reduced incidence of dry eye (Trivedi et al., 2003). 
However, a high ratio of omega-3 to omega-6 EFA appears to increase the risk of primary open 
angle glaucoma (POAG), particularly high-tension POAG (Kang et al., 2004). 
 
Contraindications of supplements 
Contraindications: pro-vitamin A 
On a previous review of the literature, beta-carotene was promoted as a preferred source of 
vitamin A due to the fact that it has virtually no adverse effects (Meyers et al., 1996). However, 
doses of 20 mg/day beta-carotene, alone or in combination with alpha-tocopherol (vitamin E) 
(The ATBC Cancer Prevention Study Group, 1994), and 30 mg/day in combination with retinyl 
palmitate (vitamin A) (Leo and Lieber, 1997) have been associated with an increased risk of 
lung cancer in smokers and those previously exposed to high levels of asbestos. The 
Physician’s Health Study found no effect of 50 mg beta-carotene every other day in a trial 
population comprising 11 % smokers (Christen et al., 2000). Hypotheses for the proposed 
increased risk of lung cancer in smokers include pro-oxidant behaviour by beta-carotene 
initiated by the high oxygen tension within the lungs, and the production of damaging oxidation 
products by the components of cigarette smoke. 
 
Beta-carotene may be contraindicated in AMD patients as plasma lutein concentration is 
reduced following multiple (Micozzi et al., 1992) and single (Kostic et al., 1995) doses. Other 
studies have, however, found no effect of beta-carotene on serum levels of lutein (Fotouhi et al., 
1996). In the ARED Study, serum levels of lutein and zeaxanthin decreased over five years, 
although changes in the treatment arm were not significantly different from the placebo arm (p > 
0.07) (The AREDS Research Group, 2001b). 
 
Contraindications: pre-formed vitamin A 
There are reports of lower bone mineral density with vitamin A supplementation (Sowers et al., 
1985), as well as increased risk of osteoporotic fracture (Melhus et al., 1998). Studies suggest 
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that bone re-absorption is stimulated by vitamin A (Jowsey and Riggs, 1968; Frame et al., 
1974), and also that vitamin A toxicity decreases bone formation (Frankel et al., 1986; Hough et 
al., 1988). Vitamin A supplementation was inversely related to the rate of change of ulna bone 
mineral content in post-menopausal women taking part in a four-year clinical trial (Freudenheim 
et al., 1986). Intake of 1500 μg retinol equivalents (RE)/day compared with 500 μg RE/day was 
associated with a total body reduction in bone mineral density of 6% (p = 0.009) and twice the 
chance of hip fracture (OR = 2.1, 95% CI = 1.1 – 4.0), although this study may be limited by 
information bias (Melhus et al., 1998). White women consuming ≥ 3000 μg RE/day had an 
increased relative risk for hip fractures (RR, 1.48; 95% CI, 1.05 – 2.07) compared to those 
taking < 1250 μg RE/day (Feskanich et al., 2002), and retinol intake has been associated with 
decreased bone mineral density and increased bone loss at total daily intakes above 840 μg 
(Promislow et al., 2002). 
However, daily supplementation with 7576 μg of retinol palmitate for six weeks did not affect the 
serum markers of skeletal turnover in healthy men (Kawahara et al., 2002), and no significant 
association between fasting serum retinyl esters and bone mineral density was found in a 
population of 5790 women aged 20 years or over (Ballew et al., 2001). 
 
Teratogenic effects have been reported with high doses of retinoic acid consumed within the 
first six weeks of pregnancy (Lammer et al., 1985). It has been suggested that vitamin A doses 
should not exceed 10 000 IU/d during pregnancy (Bauernfeind, 1972); this dosage has been 
shown to maintain blood vitamin A levels in the mother without increasing them in the newborn 
(Pereira and Begum, 1976).   
 
Vitamin A supplements have been shown to increase the tendency towards abnormal bleeding 
in rats (Walker et al., 1947; Doisey, 1961; Schrogie, 1975), which may indicate that it interacts 
with vitamin K.  Vitamin K is required for production of coagulation proteins, and so deficiency 
reduces blood coagulation. This effect has yet to be determined in humans. 
 
Valporoic acid (anticonvulsant) may interfere with the body’s ability to handle vitamin A (Nau et 
al., 1995). 
 
Isotretinoin is a modified vitamin A molecule used to treat severe acne vulgaris, which has 
above average toxicity potential. People taking isotretinoin should avoid additional vitamin A 
supplements as little is known about how the two interact. Combined administration of 
isotretinoin and vitamin E may reduce the initial toxicity of high-dose isotretinoin without 
reducing its efficacy (Dimery et al., 1997). High dose vitamin A and isotretinoin should be 
avoided by women who might become pregnant, patients with liver disease, and those who 
drink heavily. 
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Contraindications: vitamin C 
Large doses of vitamin C are generally well-tolerated. Vitamin C was investigated with regard to 
a possible interaction with oral anticoagulants following reports of an unexpected decrease in 
pro-thrombin time in people taking warfarin (Rosenthal, 1971; Smith et al., 1972). No change in 
coagulation status occurred in humans supplemented with 1 g/day for 14 days (Hume et al., 
1972). Impaired blood coagulation time (Barness, 1975) and interference with anticoagulant 
therapy (Sigell and Flessa, 1970) have been reported when doses ≥ 1 g are ingested routinely 
for months or years. Interestingly, studies suggest that the anti-platelet drug, aspirin, promotes 
loss of vitamin C via the urine (Molloy and Wilson, 1980; Das and Nebioglu, 1992). 
 
Reduced bactericidal activity of leucocytes (Shilotri and Bhat, 1977), reduced insulin production 
(Levey and Sutur, 1946) may occur with routine doses ≥ 1 g over months or years. High doses 
of vitamin C have also been reported to interfere with the breakdown of acetominophen 
(Houston and Levy, 1976). 
 
Contraindications: vitamin E 
A randomised controlled trial (RCT) showed that 400 IU/day vitamin E may have an adverse 
effect on the progress of common forms of retinitis pigmentosa (RP) (Berson et al., 1993). 
Participants taking this dosage of 400 IU/day vitamin E had a faster rate of decline in 
electroretinogram amplitude that those taking 3 IU/day. The decline rates were 11.8 % and 10.0 
% for the dosage levels respectively. Investigators hypothesised that the 400 IU/day dosage of 
vitamin E may inhibit the absorption or transport of vitamin A, as the participants receiving this 
dosage of vitamin E had significantly decreased serum retinol levels compared with those not 
receiving vitamin E (p = 0.03). 
 
Vitamin E may exacerbate the effects of vitamin K deficiency and has been associated with an 
increased risk of haemorrhagic stroke, and a reduced risk of ischaemic stroke and ischaemic 
heart disease (The ATBC Cancer Prevention Study Group, 1994). Other studies have found no 
relationship between vitamin E and haemorrhagic stroke (Gillian et al., 1977; Ascherio et al., 
1999; GISSI-Prevenzione Investigators, 1999; Leppala et al., 2000a; Yusuf et al., 2000; Primary 
Prevention Project, 2001; Heart Protection Study Collaborative Group, 2002), and smokers with 
diabetes may represent a subset of the population that may benefit from 50 IU vitamin E per 
day without experiencing an increased risk of bleeding (Leppala et al., 2000a).  
 
Oral anticoagulants, such as warfarin, antagonise the effects of vitamin K and are indicated in 
deep-vein thrombosis and pulmonary embolism patients.  The action of oral anticoagulants may 
be increased by concurrent administration of vitamin E. Concurrent vitamin E and warfarin use 
has been associated with abnormal bleeding (Corrigan and Marcus, 1974), and vitamin E 
appears to add to aspirin’s blood thinning effect (Liede et al., 1998; Leppala et al., 2000b). 
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However, vitamin E does not cause coagulation abnormalities in those who do not have 
coagulation abnormalities (Diplock, 1995). It has been suggested that anticoagulant-treated 
patients should avoid megadoses of vitamin E. 
 
Contraindications: zinc 
Patients with type I diabetes should consult their doctor before starting zinc supplementation as 
it has been reported to increase glycosylation (Cunningham et al., 1994). Glycosylation refers to 
the addition of glucose to proteins, which is thought to be responsible for some of the clinical 
manifestations of the disease (Otsuji and Kamada, 1982; Huntley, 1995). Zinc supplementation 
has, however, been shown to reduce blood sugar levels in those with type 1 diabetes (Rao et 
al., 1987), although it may not improve blood sugar levels in type 2 diabetes (Niewoehner et al., 
1986).  
 
Contraindications: Ginkgo biloba 
Gingko biloba may thin the blood, and should be avoided prior to surgery, and also by those 
taking certain anticoagulant and antiplatelet drugs (Rosenblatt and Mindel, 1997; Matthews, 
1998). 
 
Adverse reactions 
Adverse reactions: pro-vitamin A 
Individuals consuming ≥ 30 mg beta-carotene/day may experience hypercarotenemia (high 
plasma beta-carotene), which has also been observed in infants fed commercial foods 
containing large amounts of ground carrots (Lascari, 1981). The only adverse effect of 
hypercarotenemia is a reversible yellowing of the skin (hypercarotenodermia). Babies born with 
hypercarotenemia from high maternal intakes were otherwise normal, and so beta-carotene is 
not considered significantly toxic to the human foetus (Mathews-Roth, 1988). 
 
Adverse reactions: pre-formed vitamin A 
Globally, the incidence of vitamin A toxicity, or hypervitaminosis A  is a minor problem (200 
cases per year) compared with the incidence of vitamin A deficiency (VAD) (1 million cases per 
year) (Bauernfeind, 1980). In 118 countries where foods lacking in carotene are staple, VAD is 
a serious public health problem (World Health Organisation, 2003), combated by a successful 
WHO supplementation programme (Vijayaraghavan et al., 1975). In young children, 100 000 IU 
of vitamin A at 6 – 11 months and 200 000 IU given every 3 to 6 months for children aged 
between 12 and 60 months gives few side effects and is effective for reducing mortality (Beaton 
et al., 1993). Nausea, vomiting, headache, diarrhoea and fever have, however, been reported in 
some children in the Phillipines with doses of 100 000 and 200 000 IU (Florentino et al., 1990).  
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Symptoms of adult toxicity have, however been reported with single or short-term doses of 
about 50 000 IU (Bendich and Langseth, 1989), and include nausea, vomiting, increased 
cerebrospinal fluid pressure, headaches, blurred vision, and lack of muscular coordination. 
Chronic toxicity, resulting from long term consumption of high dose vitamin A include vomiting, 
weight loss, bone abnormalities, headache, fever, an enlarged liver and raised intracranial 
pressure (Bush and Dahms, 1984). Women may experience menstrual disturbances. Response 
times for vitamin A toxicity range from 6 – 108 months for a dose of 100 000 IU per day, and 
days or weeks for doses of 1 000 000 IU per day (Bauernfeind, 1980).  
 
Vitamin A has been used therapeutically in retinitis pigmentosa (Berson et al., 1993). A study 
showed that long-term supplementation with 15 000 IU daily vitamin A in healthy adults aged 18 
– 54 years elicited no adverse effects, and no evidence of hepatic toxicity (Sibulesky et al., 
1999) 
 
Vitamin A has been shown to reduce vitamin E activity (an important antioxidant) by as much as 
30% (Anon., 1985), although plasma levels of vitamin E were not affected in a human study of 
25 000 IU/day vitamin A given for 16 weeks (Willett et al., 1983). In animal models, vitamin E 
has been shown to protect membranes against vitamin A hypervitaminosis-induced damage 
(Soliman, 1972). Animal studies have shown that vitamins A and D decrease the toxic effects of 
each other (Metz et al., 1985), and also that zinc may be specifically involved in mobilizing 
vitamin A from the liver to the circulation within a short period (Ette et al., 1979). 
 
The symptoms of hypervitaminosis-A are usually relieved within a week of discontinuation, but 
long-term or irreversible effects can include cirrhosis (Hruban et al., 1974) and bone changes 
(Bauernfeind, 1980). 
 
Adverse reactions: vitamin C 
Doses of vitamin C up to 2000 mg per day are well-tolerated, although stomach cramps, 
nausea, and diarrhoea may occur with higher doses (Olson and Hodges, 1987). An review of 
the literature concluded that high doses of vitamin C are safe and free of side effects (Diplock, 
1995). 
 
Adverse reactions: zinc 
Zinc interacts with copper by stimulating metallothionein levels of the intestinal wall.  
Metallothionein binds to dietary copper preventing absorption, which leads to copper deficiency.  
This can result in copper deficiency anaemia, since copper is required for production of 
erythrocytes (Dunlap et al., 1974; Fischer et al., 1983; Flanagan et al., 1983). 
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Daily supplementation with more than 300 mg zinc per day has been associated with 
impairment of immune function (Broun et al., 1990). There are reports of a potential role of zinc 
in Alzheimer-associated neuropathogenesis (Bush et al., 1994), although more recent evidence 
from four patients showed an improvement in mental function with zinc supplementation 
(Potocnik et al., 1997). 
 
Acute zinc toxicity has been reported with doses of 200 mg or more (Expert Group on Vitamins 
and Minerals, 2003). In one study 20 female and 21 male volunteers were given 150 mg/day 
zinc for six weeks (Samman and Roberts, 1987). Symptoms including headaches, nausea, 
abdominal cramps, loss of appetite and vomiting were reported in 85 % of the female and 18 % 
of the male volunteers. These were particularly apparent when small meals or no food was 
taken with the supplements. The investigators suggested that the high percentage of females 
experiencing side-effects could be attributed to their lower body weight. 
 
Adverse reactions: Ginkgo biloba 
One case report associated long term use of GBE with bilateral subdural haematomas and 
increased bleeding time in a healthy 33-year old female (Rowin and Lewis, 1996).  
 
Conclusions 
Practitioners should be particularly aware of potential relationships between vitamin A and 
reduced bone mineral density, beta-carotene and an increased risk of lung cancer in smokers, 
and the anticoagulant and anti-platelet effects of vitamin E and Ginkgo biloba respectively 
(Liede et al., 1998). Vitamin A supplements should be avoided by women who may become 
pregnant, in those with liver disease and those who drink heavily. 
 
When discussing ocular nutritional supplements with patients, practitioners should be aware of 
the contraindications and the potential for adverse reactions. Those contraindicated from certain 
supplements, or identified as at risk of adverse reaction, should be advised to discuss 
supplementation with their medical practitioner.  
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Nutrient Sources Main functions Recommended 
daily  
Safe upper  
Limit 
Tolerable 
upper 
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allowance for 
adults 
intake level 
(US Food 
and 
Nutirion 
Board) 
Vitamin A As vitamin 
A: fish liver 
oils, beef 
liver, egg 
yolk, butter 
and cream 
 
As 
carotenoids 
(pro-vitamin 
A): dark 
green leafy 
vegetables, 
yellow fruits 
and red 
palm oil 
Maintenance of 
vision, skin, 
lining of 
intestine, lungs 
and urinary 
tract. Helps 
protect against 
infection. Used 
as the basis of 
drugs called 
retinoids that 
are used to treat 
severe acne 
and some 
cancers. 
700-900 μg. 
1300 μg for 
pregnant and 
breastfeeding 
women. 
500 IU/d to 10 
000 IU/d 
(Meyers et al., 
1996). 
 
3000 g 
(retinol) 
Vitamin E Vegetable 
oil, wheat 
germ, leafy 
vegetables, 
egg yolk, 
margarine 
and 
legumes. 
Acts as an 
antioxidant. 
15 mg 800 IU or 540 
mg of d-α-
tocopherol 
equivalents 
(Expert Group 
on Vitamins and 
Minerals, 2003). 
1000 mg 
Vitamin B2 Milk, 
cheese, 
liver, meat, 
fish, eggs 
and 
enriched 
cereals. 
Required for 
metabolism of 
carbohydrates 
and amino acids 
and for healthy 
mucous 
membranes. 
1.1 mg women 
1.3 mg men 
- - 
Vitamin B6 Dried 
yeast, liver, 
organ 
meats, 
whole-grain 
cereals, 
fish and 
legumes. 
Required for 
metabolism of 
amino acids and 
fatty acids, for 
nerve function, 
for the formation 
of red blood 
cells and for 
healthy skin. 
1.5 mg women 
1.7 mg men 
10mg/d (Expert 
Group on 
Vitamins and 
Minerals, 2003) 
although usually 
safe up to 200 
mg/d (Gaby, 
1990). 
25 mg 
Vitamin 
B12 
Liver, meat, 
eggs, milk 
and milk 
products. 
Required for the 
metabolism of 
carbohydrates 
and fatty acids. 
2.4 μg 2 mg/d 
cyanocobalamin 
(Expert Group 
on Vitamins and 
Minerals, 2003). 
- 
Vitamin C Citrus 
fruits, 
tomatoes, 
potatoes, 
cabbage, 
and green 
peppers. 
Required for the 
formation and 
growth of bone 
and connective 
tissue, for 
healing of 
wounds and 
burns, and for 
75 mg women 
90 mg men 
 
35 mg extra for 
smokers 
2 mg (Bloch, 
2000). 
2000 mg 
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normal function 
of blood 
vessels. 
 
Acts as an 
antioxidant and 
helps the body 
to absorb iron. 
Magnesium Leafy green 
vegetables, 
nuts, 
cereal, 
grains and 
seafood 
Required for the 
formation of 
bone and teeth, 
for normal nerve 
and muscle 
function, and for 
the activation of 
enzymes. 
300 mg/d men. 
270 mg/d 
women 
Guidance level 
of 400 mg/d 
(Expert Group 
on Vitamins and 
Minerals, 2003). 
250 mg 
Selenium Meats, 
seafood, 
and cereals 
(dependant 
on the 
selenium 
content of 
the soil 
where the 
grain was 
grown). 
Acts as an 
antioxidant with 
vitamin E, 
protecting cells 
from oxidative 
damage. Also 
required for 
thyroid gland 
function. 
55 μg 500 μg (Gaby, 
1990). 
300 μg 
Zinc Organ 
meats such 
as liver, 
eggs and 
seafood. 
Used to form 
many enzymes 
and insulin. 
Required for 
healthy skin, 
healing of 
wounds, and 
growth. 
15 mg 25 mg 
supplemental 
zinc (Expert 
Group on 
Vitamins and 
Minerals, 2003). 
40 mg 
Ginkgo 
biloba 
Ginkgo 
biloba tree 
Reduction in 
platelet 
aggregation and 
the production 
of free radicals. 
Role in 
neurotransmitter 
metabolism. 
Trials have 
used between 
120 and 240 
mg/d 
- - 
Omega 3 
essential  
Fatty acids 
Fish oils 
including 
cod liver oil. 
Flaxseeds, 
linseeds, 
pumkin 
seeds, 
soya bean, 
walnut oil, 
green leafy 
vegetables, 
grains, and 
oils made 
from 
linseed, 
Maintenance of 
cell membranes 
and production 
of 
prostaglandins. 
0.2 x to 0.5 x 
amount of 
omega 6 EFA. 
- - 
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rapeseed, 
and soya 
beans. 
Omega 6 
essential 
Fatty acids 
Vegetables, 
fruits, nuts, 
grains, 
seeds and 
oils made 
from 
safflower, 
sunflower, 
corn, soya, 
Evening 
primrose, 
pumkin, 
and 
wheatgerm. 
Also dairy 
products 
and beef. 
Maintenance of 
cell membranes 
and production 
of 
prostaglandins. 
3 – 6 % of total 
calories, 
or 6 -12 g. 
- - 
 
Table 1: Summary of source, function, recommended daily allowance, and safe upper limits for 
nutrients and herbs associated with ocular health. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplement Drug Explanantion 
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Vitamin A Anticonvulsant agents Valproic acid may interfere with the body’s 
ability to handle vitamin A (Nau et al., 1995). 
Vitamin B6 Folic acid B6 may reduce the absorption or activity of 
folic acid. 
Vitamin C Acetaminophen (pain 
relief) 
High doses of vitamin C may interfere with 
normal breakdown of this drug. May result in 
liver-damaging accumulation of 
acetaminophen (Houston and Levy, 1976). 
Vitamin C Anticoagulants Impaired blood coagulation time (Barness, 
1975) and interference with anticoagulant 
therapy (Sigell and Flessa, 1970) have been 
reported when large doses (≥ 1 g) are 
ingested routinely for months or years. 
Vitamin E Warfarin 800 IU daily vitamin E caused abnormal 
bleeding when added to the effects of 
warfarin (Cirrigan and Marcus, 1974) 
Vitamin E NSAIDs Vitamin E appears to add to aspirin’s blood 
thinning effects (Liede et al., 1998; Leppala et 
al., 2000b). 
Ginkgo biloba Anticonvulsants A natural nerve toxin has been found in the 
seeds of Ginkgo biloba (Arenz et al., 
1996).This toxin could prevent 
anticonvulsants from working as expected.  
Ginkgo biloba Warfarin Ginkgo biloba appears to reduce the ability of 
platelets to stick together (Chung et al., 
1987). Ginkgo biloba may add to the blood-
thinning effects of warfarin (Matthews, 1998). 
Ginkgo biloba NSAIDs The combination of Ginkgo biloba and aspirin 
may increase the chance of abnormal 
bleeding (Rosenblatt and Mindel, 1997). 
Magnesium Amiloride (diuretic) Amiloride may reduce urinary excretion of 
magnesium in animals (Devane and Ryan, 
1981). People taking more than 300 mg 
magnesium and amiloride should consult their 
doctor. 
Magnesium  Flouroquinoline antibiotics 
Tetracyclines 
Nitrofurantoin (antibiotic)  
Magnesium can bind to these antibiotics, 
greatly decreasing the absorption of the drug 
(Holt, 1998). It is recommended to take the 
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drugs two hours after consuming mineral-
containing supplements (Threlkeld, 1994). 
Magnesium Misoprostol 
(prostaglandin E1 
analogue that protects the 
mucosal lining of the 
stomach and intestines. 
A common side effect of misoprostol is 
diarrhoea, which is aggravated by magnesium 
(Sifton, 2000). 
Magnesium Oral corticosteroids Loss of magnesium from the body may be 
increased by magnesium (Holt, 1998). 
Magnesium may interfere with absorption of 
dexamethasone (Naggar et al., 1978). 
Zinc Fluoroquinolone 
antibiotics 
Tetracyclines 
Zinc can bind to these antibiotics, greatly 
decreasing the absorption of the drug (Holt, 
1998). It is recommended to take the drugs 
two hours after consuming mineral-containing 
supplements (Threlkeld, 1994). 
 
Table 2: Drug interactions of nutritional supplements considered beneficial for ocular health. 
 
 
 
Abbreviated title 
Adverse reactions of ocular nutritional supplements. 
